Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms

Leukemia Research

Volumn 28, Issue 11, 2004, Pages 1153-1157

  Brück, Patrick ^a   Wassmann, Barbara ^a   Lopez, Elizabeth Ramos ^a   Hoelzer, Dieter ^a   Ottmann, Oliver G ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acute leukemia; Cerebral hygroma; Chronic myeloid leukemia; Imatinib mesylate; PDGF receptor; Restriction fragment length polymorphisms; Single nucleotide polymorphisms; STI571

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; EDEMA; FEMALE; GENE CONTROL; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HYGROMA; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; PROMOTER REGION; SIDE EFFECT; SIGNAL TRANSDUCTION;

EDEMA; ENZYME INHIBITORS; HUMANS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SUBDURAL EFFUSION;

EID: 4544290436     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.03.007     Document Type: Article

References (32)

1. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56(1):1996;100-104
2. Mauro M.J., O'Dwyer M., Heinrich M.C., Druker B.J. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 20:2002;325-334
3. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and Platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295(1):2000;139-145
4. Verweij J., van Oosterom A., Blay J.Y., Judson I., Rodenhuis S., van der Graaf W., et al. Imatinib mesylate (STI-571 Glivec(R) Gleevec) is an active agent for gastrointestinal stromal tumours but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer. 39(14):2003;2006-2011
5. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 358(9291):2001;1421-1423
6. van Oosterom A.T., Judson I.R., Verweij J., Stroobants S., Dumez H., Donato di Paola E., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 38(Suppl. 5):2002;S83-S87
7. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14):2001;1031-1037
8. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99:2002;1928-1937
9. Sawyers C.L., Hochhaus A., Silver R.T., Goldman J.M., Miller C., Ottmann O.G., et al. Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:2002;3530-3539
10. Kantarjian H., Sawyers C.L., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346:2002;645-652
11. Sjöblom T., Shimizu A., O'Brien K.P., Pietras K., Dal Cin P., Buchdunger E., et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61(15):2001;5778-5783
12. Global Monograph Glivec, Novartis.
13. Heldin C.-H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79(4):1999;1283-1316
14. Kazlaukas A. Receptor tyrosine kinases and their targets. Curr. Opin. Genet. Dev. 4(1):1994;5-14
15. Heuchel R., Berg A., Tallquist M., Åhlén K., Reed R.K., Rubin K., et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc. Natl. Acad. Sci. U.S.A. 6(20):1999;11410-11415
16. Pietras K., Ostman A., Sjöquist M., Buchdunger E., Reed R.K., Heldin C.H., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61(7):2001;2929-2934
17. Hossain M.Z., Ao P., Boynton A.L. Rapid disruption of gap junctional communication and phosphorylation of Connexin 43 by platelet-derived growth factor in T51B rat liver epithelial cells expressing platelet-derived growth factor receptor. J. Cell. Physiol. 174:1998;66-77
18. Lindahl P., Johansson B.R., Levéen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B deficient mice. Science. 277:1997;242-245
19. Sundberg C., Ljungstrom M., Lindmark G., Gerdin B., Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol. 143:1993;1377-1388
20. Schneller M., Vuori K., Ruoslahti E. αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J. 16:1997;5600-5607
21. Schwartz M.A., Baron V. Interactions between mitogenic stimuli, or, a thousand and one connections. Curr. Opin. Cell Biol. 11:1999;197-202
22. Baron V., Schwartz M. Cell adhesion regulates ubiquitin-mediated degradation of the Platelet-derived growth factor receptor β J. Biol. Chem. 272(15):2000;39318-39323
23. Ebnoether M., Stentoft J., Ford J., Buhl L., Gratwohl A. Cerebral oedema as a possible complication of treatment with imatinib. Lancet. 359(9319):2002;1751-1752
24. Esmaeli B., Prieto V.G., Butler C.E., Kim S.K., Ahmadi M.A., Kantarjian H.M., et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 95(4):2002;881-887
25. Goldsby R., Pulsipher M., Adams R., Coffin C., Albritton K., Wagner L. Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J. Pediatr. Hematol. Oncol. 24(8):2002;694-695
26. Hensley M.L., Ford J.M. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin. Hematol. 40(2 Suppl 2):2003;21-25
27. Ramar K., Potti A., Mehdi S.A. Uncommon syndromes and treatment manifestations of malignancy. Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. J. Clin. Oncol. 21(1):2003;172-173
28. Shimazaki C., Ochiai N., Uchida R., Fuchida S.I., Okano A., Ashihara E., et al. Intramuscular edema as a complication of treatment with imatinib. Leukemia. 17(4):2003;804-805
29. Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers J., Silver R.T., et al. A phase II study of imatinib mesylate (Glivec™) in patients with relapsed or refractory philadelphia chromosome-positive acute lymphoid leukemias. Blood. 100:2002;1965-1971
30. Wiley J.S., Dao-Ung L.P., Gu B.J., Sluyter R., Shemon A.N., Li C., et al. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet. 359(9312):2002;1114- 1119
31. Schwahn B., Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am. J. Pharmacogenomics. 1(3):2002;189-201
32. Illmer T., Schuler U.S., Thiede C., Schwarz U.I., Kim R.B., Gotthard S., et al. DR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62(17):2002;4955-4962